Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;11(4):161-172.
doi: 10.5582/irdr.2022.01109.

Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update

Xinyi Zhang  1 , Yulong Cai  1 , Xianze Xiong  1 , Ao Liu  1 , Rongxin Zhou  1 , Zhen You  1 , Fuyu Li  1 , Nansheng Cheng  1
Affiliations
Review

Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update

Xinyi Zhang et al. Intractable Rare Dis Res. 2022 Nov.

Abstract

As a consequence of breakthroughs in the area of guidelines research, the therapy for cholangiocarcinoma has significantly improved the efficacy rate of diagnosis and survival outcomes. We compared the most recently updated clinical practice guidelines and consensus to provide recommendations based on the diagnostic and therapeutic equipment available in various countries. Following a systematic review, we discovered that these guidelines and consensus had both similarities and differences in terms of what organizations or groups drafted the guidelines and the approach, applicability, content and recent updates of the guidelines as well as in terms of diagnostic and treatment algorithms. The disparities could be attributable to a variety of etiological factors, high risk patients, health resources, medical technology, treatment options, and income levels. Additionally, while complete adoption of guidelines may benefit physicians, patients, and authorities, there remains a disconnect between expected goals and implementation.

Keywords: cholangiocarcinoma; clinical practice guideline; diagnosis; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Algorithm for the management of patients with cholangiocarcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383:2168-2179. - PMC - PubMed
    1. Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:7-18. - PubMed
    1. Cardinale V. Classifications and misclassification in cholangiocarcinoma. Liver Int. 2019; 39:260-262. - PubMed
    1. Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. Lancet. 2021; 397:428-444. - PubMed
    1. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76:182-188. - PMC - PubMed